Featured News
All News
New Clinical Trial Focused on Relapse Prevention in Patients with Acute Myeloid Leukemia Undergoing Bone Marrow Transplant
Investigator-Initiated Trial; Only Available at Siteman Cancer Center, Siteman Kids in St. Louis ST. LOUIS — A new and promising clinical trial aimed at preventing relapse in patients diagnosed with acute myeloid leukemia (AML) is now open at Washington University School of Medicine in St. Louis. The trial
New Clinical Trials Open for Sarcomas and Solid Tumors
Two exciting early phase clinical trials are underway at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, that leverage novel classes of drugs and exploit how proteins can be targeted and/or removed to stop uncontrolled cell division that occurs in sarcomas and
Whole Genome Sequencing for AML/MDS Risk Stratification
ChromoSeq now covered by Medicare; Two Clinical Trials Also Open Two novel clinical trials for patients diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) are open and enrolling patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The clinical trials
Siteman Cancer Center Advances Head and Neck Tumor Discovery
Soon, a global, stage III randomized clinical trial could result in a paradigm shift in how certain head and neck cancers are treated. The clinical trial, called KEYNOTE-689 and overseen by the Merck pharmaceutical company, is the result of specific research initiated by head and neck cancer specialists at Siteman
Washington University School of Medicine in St. Louis Awarded $10.9 Million SPORE Grant for Pancreas Cancer
New Clinical Trials Set for Pancreatic Ductal Adenocarcinoma Clinical researchers at Washington University School of Medicine in St. Louis have been awarded a Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) to continue clinical trials and research aimed at advancing pancreatic cancer care. Awarded in
Treating Multiple Myeloma — New Immunotherapies
Multiple myeloma has long vexed medical researchers because of the cancer’s specific ability to both weaken and “hide” from a patient’s own immune system. The result is that while many treatments have been able to treat the disease for some time, patients subsequently relapse. But newer medications now can
New Clinical Trial Focused on Relapse Prevention in Patients with Acute Myeloid Leukemia Undergoing Bone Marrow Transplant
Investigator-Initiated Trial; Only Available at Siteman Cancer Center, Siteman Kids in St. Louis ST. LOUIS — A new and promising clinical trial aimed at preventing relapse in patients diagnosed with acute myeloid leukemia (AML) is now open at Washington University School of Medicine in St. Louis. The trial
New Clinical Trials Open for Sarcomas and Solid Tumors
Two exciting early phase clinical trials are underway at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, that leverage novel classes of drugs and exploit how proteins can be targeted and/or removed to stop uncontrolled cell division that occurs in sarcomas and
Whole Genome Sequencing for AML/MDS Risk Stratification
ChromoSeq now covered by Medicare; Two Clinical Trials Also Open Two novel clinical trials for patients diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) are open and enrolling patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The clinical trials
Siteman Cancer Center Advances Head and Neck Tumor Discovery
Soon, a global, stage III randomized clinical trial could result in a paradigm shift in how certain head and neck cancers are treated. The clinical trial, called KEYNOTE-689 and overseen by the Merck pharmaceutical company, is the result of specific research initiated by head and neck cancer specialists at Siteman
Washington University School of Medicine in St. Louis Awarded $10.9 Million SPORE Grant for Pancreas Cancer
New Clinical Trials Set for Pancreatic Ductal Adenocarcinoma Clinical researchers at Washington University School of Medicine in St. Louis have been awarded a Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) to continue clinical trials and research aimed at advancing pancreatic cancer care. Awarded in
Treating Multiple Myeloma — New Immunotherapies
Multiple myeloma has long vexed medical researchers because of the cancer’s specific ability to both weaken and “hide” from a patient’s own immune system. The result is that while many treatments have been able to treat the disease for some time, patients subsequently relapse. But newer medications now can
Make a Referral
Refer a patient to a Washington University Physician at Siteman Cancer Center.
Physician Services
Contact our physician liaison team for more information about Siteman Cancer Center services, physicians and programs.
Subscribe to Our Newsletter
Receive the latest updates on Siteman Cancer Center services, physicians, educational programs and more.